HCPCS codes

63646 HCPCS codes with hospital pricing data in the network.

Sorted by number of hospitals reporting each code, most first.

• HCPCS Q4082 — Drug or biological, not otherwise classified, part b drug competitive acquisition program (cap) (48 hospitals)
• HCPCS S0142 — Colistimethate sodium, inhalation solution administered through dme, concentrated form, per mg (48 hospitals)
• HCPCS S3620 — Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogest (48 hospitals)
• HCPCS S3630 — Eosinophil count, blood, direct (48 hospitals)
• HCPCS S3645 — Hiv-1 antibody testing of oral mucosal transudate (48 hospitals)
• HCPCS S3650 — Saliva test, hormone level; during menopause (48 hospitals)
• HCPCS S3652 — Saliva test, hormone level; to assess preterm labor risk (48 hospitals)
• HCPCS S3655 — Antisperm antibodies test (immunobead) (48 hospitals)
• HCPCS S3800 — Genetic testing for amyotrophic lateral sclerosis (als) (48 hospitals)
• HCPCS S3840 — Dna analysis for germline mutations of the ret proto-oncogene for susceptibility to multiple endocrine neoplasia type 2 (48 hospitals)
• HCPCS S3841 — Genetic testing for retinoblastoma (48 hospitals)
• HCPCS S3842 — Genetic testing for von hippel-lindau disease (48 hospitals)
• HCPCS S3844 — Dna analysis of the connexin 26 gene (gjb2) for susceptibility to congenital, profound deafness (48 hospitals)
• HCPCS S3845 — Genetic testing for alpha-thalassemia (48 hospitals)
• HCPCS S3846 — Genetic testing for hemoglobin e beta-thalassemia (48 hospitals)
• HCPCS S3849 — Genetic testing for niemann-pick disease (48 hospitals)
• HCPCS S3850 — Genetic testing for sickle cell anemia (48 hospitals)
• HCPCS S3852 — Dna analysis for apoe epsilon 4 allele for susceptibility to alzheimer's disease (48 hospitals)
• HCPCS S3853 — Genetic testing for myotonic muscular dystrophy (48 hospitals)
• HCPCS S3854 — Gene expression profiling panel for use in the management of breast cancer treatment (48 hospitals)
• HCPCS S8035 — Magnetic source imaging (48 hospitals)
• HCPCS S8037 — Magnetic resonance cholangiopancreatography (mrcp) (48 hospitals)
• HCPCS S8040 — Topographic brain mapping (48 hospitals)
• HCPCS S8042 — Magnetic resonance imaging (mri), low-field (48 hospitals)
• HCPCS S8085 — Fluorine-18 fluorodeoxyglucose (f-18 fdg) imaging using dual-head coincidence detection system (non-dedicated pet scan) (48 hospitals)
• HCPCS S8092 — Electron beam computed tomography (also known as ultrafast ct, cine ct) (48 hospitals)
• HCPCS S9034 — Extracorporeal shockwave lithotripsy for gall stones (if performed with ercp, use 43265) (48 hospitals)
• HCPCS J8498 — Antiemetic drug, rectal/suppository, not otherwise specified (48 hospitals)
• HCPCS L8607 — Injectable bulking agent for vocal cord medialization, 0.1 ml, includes shipping and necessary supplies (48 hospitals)
• HCPCS Q0085 — Chemotherapy administration by both infusion technique and other technique(s) (e.g., subcutaneous, intramuscular, push), per visit (48 hospitals)
• HCPCS C9741 — Right heart catheterization with implantation of wireless pressure sensor in the pulmonary artery, including any type of measurement, angiography, imaging supervision, interpretation, and report (48 hospitals)
• HCPCS H0015 — Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessmen (48 hospitals)
• HCPCS J9255 — Injection, methotrexate (accord), not therapeutically equivalent to j9260, 50 mg (48 hospitals)
• HCPCS S9480 — Intensive outpatient psychiatric services, per diem (48 hospitals)
• HCPCS H0035 — Mental health partial hospitalization, treatment, less than 24 hours (48 hospitals)
• HCPCS J0166 — Injection, epinephrine (bpi), not therapeutically equivalent to j0165, 0.1 mg (48 hospitals)
• HCPCS J0169 — Injection, epinephrine (adrenalin), not therapeutically equivalent to j0165, 0.1 mg (48 hospitals)
• HCPCS J1326 — Injection, zolbetuximab-clzb, 2 mg (48 hospitals)
• HCPCS Q4211 — Amnion bio or axobiomembrane, per square centimeter (add-on, list separately in addition to primary procedure) (48 hospitals)
• HCPCS C9176 — Tc-99m from domestically produced non-heu mo-99, ºminimum 50 percent», full cost recovery add-on, per study dose (48 hospitals)
• HCPCS J0654 — Injection, liothyronine, 1 mcg (48 hospitals)
• HCPCS J2516 — Injection, pentamidine isethionate, 1 mg (48 hospitals)
• HCPCS J3291 — Injection, tranexamic acid in sodium chloride, 5 mg (48 hospitals)
• HCPCS J7528 — Mycophenolate mofetil, for suspension, oral, 100 mg (48 hospitals)
• HCPCS A2002 — Mirragen advanced wound matrix, per square centimeter (add-on, list separately in addition to primary procedure) (48 hospitals)
• HCPCS A2006 — Novosorb synpath dermal matrix, per square centimeter (add-on, list separately in addition to primary procedure) (48 hospitals)
• HCPCS A2010 — Apis, per square centimeter (add-on, list separately in addition to primary procedure) (48 hospitals)
• HCPCS A2012 — Suprathel, per square centimeter (add-on, list separately in addition to primary procedure) (48 hospitals)
• HCPCS A2016 — Permeaderm b, per square centimeter (add-on, list separately in addition to primary procedure) (48 hospitals)
• HCPCS A2018 — Permeaderm c, per square centimeter (add-on, list separately in addition to primary procedure) (48 hospitals)